Company intelligence / Profile preview

iVeena Delivery Systems

Salt Lake City, Utah, United Statesiveenamed.com ↗

Ownership: Private
Employees: ~8
Development stage: Phase 2

Overview

iVeena has completed a Phase 1/2a pilot clinical study for IVMED-80 for keratoconus. IVMED-85 for myopia is in Phase 1/2 and expected to begin Phase 2 clinical study in 2025. The company recently secured $3 million in Series B-2 financing to accelerate development of IVMED-85.

Therapeutic areas: Ophthalmology
Modalities: Small molecule drugs
Industry: Biotech

Drug pipeline

5 assets

IVMED-85

4 more assets in the full pipeline.

Request access →

Partnerships

Glaukos Corporation (licensed lead asset IVMED-80)

Beyond the preview

Go deeper on iVeena Delivery Systems.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iVeena Delivery Systems.

Explore the full profile